Lupin Partners with Valorum for Biosimilar Armlupeg
Dec 04, 2025 16:19
Lupin inks licensing deal with Valorum Biologics to commercialize Armlupeg, a biosimilar for neutropenia treatment in cancer patients in the US.
New Delhi, Dec 4 (PTI) Drug maker Lupin on Thursday said it has inked a licensing pact with US-based Valorum Biologics to commercialise Armlupeg, a biosimilar indicated for the treatment of neutropenia in cancer patients.
Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US, while Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.
"This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines," said Spiro Gavaris, President US Generics, Lupin.
Armlupeg is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
"Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise," Valorum CEO Par S Hyare stated.
Lupin shares ended 0.55 per cent up at Rs 2,091.95 apiece on BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read